Koronis Pharma: Shaping the Future of Antiviral Therapies
Koronis Pharma focuses on the challenges of viral infections such as HIV and hepatitis. Despite the availability of several antiviral treatments, viral resistance remains a major factor in treatment failure. Resistance not only affects the drug being used but can also extend to other drugs in the same class, making the management of these infections more difficult.

Our Strategy
Our goal is to develop novel antiviral agents that can effectively target resistant viral strains while minimizing the risk of further resistance development. Utilizing advanced platform technologies, we aim to engineer therapies that overcome the limitations of existing treatments. Through rigorous preclinical and clinical evaluations, we work to validate and optimize these therapies for broader clinical application.
Addressing Resistance in HIV and Hepatitis Solution
Addressing Resistance in HIV/AIDS Treatment
At Koronis, we are dedicated to tackling the growing problem of resistance in the treatment of HIV/AIDS. In the U.S., while 21 therapies have been approved for the treatment of HIV, resistance continues to present a significant challenge. Resistance occurs when the virus evolves in such a way that the current treatment becomes less effective or even ineffective. This phenomenon leads to treatment failure and complicates the management of the disease. A key concern is that when a patient develops resistance to one particular treatment, they may also develop resistance to other therapies in the same class, even if those treatments have not been used previously. This widespread issue of resistance underscores the need for continued innovation in the development of effective treatments for HIV.
Hepatitis and the Need for Improved Treatments
Hepatitis, a viral infection that affects the liver, impacts a significant portion of the population, and in the U.S., it affects four times more individuals than HIV/AIDS. Despite the large number of people impacted, the available treatment options for hepatitis are limited, primarily consisting of interferons and ribavirin. While these therapies can work for some, they are not universally effective and are often associated with side effects that limit their use. The availability of only a few treatment options makes it particularly difficult for individuals who are co-infected with both HIV and hepatitis to manage their conditions effectively. This gap in treatment options highlights the urgent need for new and more effective therapies to address both HIV and hepatitis infections.
Our Approach: Developing Innovative Antiviral Solutions
At Koronis, we are focused on advancing the development of novel antiviral solutions that can more effectively address the challenges posed by resistant viruses. Our approach involves leveraging cutting-edge technology to discover and develop therapies that not only target the virus but also have a lower likelihood of resistance development. By focusing on the mechanisms that enable viruses to evolve and adapt, we aim to create treatments that provide long-term efficacy for patients. Through rigorous clinical trials, we test the safety and effectiveness of these new therapies, working to provide better treatment options for individuals living with HIV and hepatitis. Our goal is to improve the quality of life for patients and contribute to the ongoing fight against these chronic viral infections.
